Trial Profile

Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004)in the Treatment of Ankylosing Spondylitis (AS).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apremilast (Primary)
Indications Ankylosing spondylitis
Focus Therapeutic Use
Acronyms START

Most Recent Events

14 Sep 2012 Results published in Annals of the Rheumatic Diseases.
14 Sep 2012 Primary endpoint 'Bath-Ankylosing-Spondylitis-Disease-Activity-Index' has not been met, according to results published ARD.
07 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com